Patents by Inventor Kim J. Hasenkrug

Kim J. Hasenkrug has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CD47 TARGETED THERAPIES FOR THE TREATMENT OF INFECTIOUS DISEASE
    Publication number: 20230406952
    Abstract: Methods are provided for treating a subject with for an intracellular pathogen infection, by administering an agent that reduces the binding of CD47 on a infected cell to SIRP? on a host phagocytic cell, in an effective dose for increasing the phagocytosis of infected cells.
    Type: Application
    Filed: August 30, 2023
    Publication date: December 21, 2023
    Inventors: Kipp Andrew Weiskopf, Kim J. Hasenkrug, Cheryl A. Stoddart, Joseph M. McCune, Irving L. Weissman
  • CD47 targeted therapies for the treatment of infectious disease
    Patent number: 11780931
    Abstract: Methods are provided for treating a subject with for an intracellular pathogen infection, by administering an agent that reduces the binding of CD47 on a infected cell to SIRP? on a host phagocytic cell, in an effective dose for increasing the phagocytosis of infected cells.
    Type: Grant
    Filed: December 14, 2021
    Date of Patent: October 10, 2023
    Assignees: The Board of Trustees of the Leland Stanford Junior University, The United States of America, as represented by the Secretary, Department of Health and Human Services, The Regents of the University of California
    Inventors: Kipp Andrew Weiskopf, Kim J. Hasenkrug, Cheryl A. Stoddart, Joseph McCrary McCune, Irving L. Weissman
  • SIRPa EXPRESSION ON T CELLS IS A BIOMARKER FOR FUNCTIONAL T CELLS DURING EXHAUSTION
    Publication number: 20220120731
    Abstract: Prolonged exposure of CD8+ T cells to antigenic stimulation leads to a state of diminished function, termed exhaustion; during exhaustion there is a subset of functional CD8+ T cells defined by surface expression of SIRP(alpha) protein. On SIRP+ CD8+ T cells, expression of coinhibitmy receptors is counterbalanced by expression of co-stimulatory receptors and it is only these SIRP+ cells that actively proliferate, transcribe IFNg and show cytolytic activity. Therapeutic blockade of PD-L1 or other inhibitory receptors to reinvigorate exhausted CD8+ T cells expands the cytotoxic subset of SIRP+ CD8+ T cells.
    Type: Application
    Filed: January 30, 2020
    Publication date: April 21, 2022
    Inventors: Michal Caspi Tal, Lara Myers, Kim J. HasenKrug, Ying Ying Yiu, Irving L. Weissman
  • CD47 TARGETED THERAPIES FOR THE TREATMENT OF INFECTIOUS DISEASE
    Publication number: 20220098322
    Abstract: Methods are provided for treating a subject with for an intracellular pathogen infection, by administering an agent that reduces the binding of CD47 on a infected cell to SIRP? on a host phagocytic cell, in an effective dose for increasing the phagocytosis of infected cells.
    Type: Application
    Filed: December 14, 2021
    Publication date: March 31, 2022
    Inventors: Kipp Andrew Weiskopf, Kim J. Hasenkrug, Cheryl A. Stoddart, Joseph McCrary McCune, Irving L. Weissman
  • CD47 targeted therapies for the treatment of infectious disease
    Patent number: 11230607
    Abstract: Methods are provided for treating a subject with for an intracellular pathogen infection, by administering an agent that reduces the binding of CD47 on a infected cell to SIRP? on a host phagocytic cell, in an effective dose for increasing the phagocytosis of infected cells.
    Type: Grant
    Filed: June 15, 2020
    Date of Patent: January 25, 2022
    Assignees: The Board of Trustees of the Leland Stanford Junior University, The United States of America as represented by the Secretary, Department of Health and Human Services, The Regents of the University of California
    Inventors: Kipp Andrew Weiskopf, Kim J. Hasenkrug, Cheryl A. Stoddart, Joseph McCrary McCune, Irving L. Weissman
  • CD47 TARGETED THERAPIES FOR THE TREATMENT OF INFECTIOUS DISEASE
    Publication number: 20200354469
    Abstract: Methods are provided for treating a subject with for an intracellular pathogen infection, by administering an agent that reduces the binding of CD47 on a infected cell to SIRP? on a host phagocytic cell, in an effective dose for increasing the phagocytosis of infected cells.
    Type: Application
    Filed: June 15, 2020
    Publication date: November 12, 2020
    Inventors: Kipp Andrew Weiskopf, Kim J. Hasenkrug, Cheryl A. Stoddart, Joseph McCrary McCune, Irving L. Weissman
  • CD47 targeted therapies for the treatment of infectious disease
    Patent number: 10723803
    Abstract: Methods are provided for treating a subject with for an intracellular pathogen infection, by administering an agent that reduces the binding of CD47 on a infected cell to SIRP? on a host phagocytic cell, in an effective dose for increasing the phagocytosis of infected cells.
    Type: Grant
    Filed: December 10, 2018
    Date of Patent: July 28, 2020
    Assignees: The Board of Trustees of the Leland Stanford Junior University, The United States of America, as represented by the Secretary, Department of Health and Human Services, The Regents of the University of California
    Inventors: Kipp Andrew Weiskopf, Kim J. Hasenkrug, Cheryl A. Stoddart, Joseph McCrary McCune, Irving L. Weissman
  • CD47 TARGETED THERAPIES FOR THE TREATMENT OF INFECTIOUS DISEASE
    Publication number: 20190092873
    Abstract: Methods are provided for treating a subject with for an intracellular pathogen infection, by administering an agent that reduces the binding of CD47 on a infected cell to SIRP? on a host phagocytic cell, in an effective dose for increasing the phagocytosis of infected cells.
    Type: Application
    Filed: December 10, 2018
    Publication date: March 28, 2019
    Inventors: Kipp Andrew Weiskopf, Kim J. Hasenkrug, Cheryl A. Stoddart, Joseph McCrary McCune, Irving L. Weissman
  • CD47 targeted therapies for the treatment of infectious disease
    Patent number: 10184004
    Abstract: Methods are provided for treating a subject with for an intracellular pathogen infection, by administering an agent that reduces the binding of CD47 on a infected cell to SIRP? on a host phagocytic cell, in an effective dose for increasing the phagocytosis of infected cells.
    Type: Grant
    Filed: August 14, 2017
    Date of Patent: January 22, 2019
    Assignees: The Board of Trustees of the Leland Stanford Junior University, The Regents of the University of California, The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Kipp Andrew Weiskopf, Kim J. Hasenkrug, Cheryl A. Stoddart, Joseph McCrary McCune, Irving L. Weissman
  • CD47 TARGETED THERAPIES FOR THE TREATMENT OF INFECTIOUS DISEASE
    Publication number: 20170362332
    Abstract: Methods are provided for treating a subject with for an intracellular pathogen infection, by administering an agent that reduces the binding of CD47 on a infected cell to SIRP? on a host phagocytic cell, in an effective dose for increasing the phagocytosis of infected cells.
    Type: Application
    Filed: August 14, 2017
    Publication date: December 21, 2017
    Inventors: Kipp Andrew Weiskopf, Kim J. Hasenkrug, Cheryl A. Stoddart, Joseph McCrary McCune, Irving L. Weissman
  • CD47 targeted therapies for the treatment of infectious disease
    Patent number: 9771428
    Abstract: Methods are provided for treating a subject with for an intracellular pathogen infection, by administering an agent that reduces the binding of CD47 on a infected cell to SIRP? on a host phagocytic cell, in an effective dose for increasing the phagocytosis of infected cells.
    Type: Grant
    Filed: February 5, 2014
    Date of Patent: September 26, 2017
    Assignees: The Board of Trustees of the Leland Stanford Junior University, The Regents of the University of California, The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Kipp Andrew Weiskopf, Kim J. Hasenkrug, Cheryl A. Stoddart, Joseph M. McCune, Irving L. Weissman
  • CD47 Targeted Therapies for the Treatment of Infectious Disease
    Publication number: 20150376288
    Abstract: Methods are provided for treating a subject with for an intracellular pathogen infection, by administering an agent that reduces the binding of CD47 on a infected cell to SIRP? on a host phagocytic cell, in an effective dose for increasing the phagocytosis of infected cells.
    Type: Application
    Filed: February 5, 2014
    Publication date: December 31, 2015
    Inventors: Kipp Andrew Weiskopf, Kim J. Hasenkrug, Cheryl A. Stoddart, Joseph M. McCune, Irving L. Weissman